Nesiritide during extracorporeal membrane oxygenatio

Paediatric Anaesthesia 15, 152-157

DOI: 10.1111/j.1460-9592.2004.01398.x

Citation Report

#	Article	IF	CITATIONS
1	The neurohormonal axis and biochemical markers of heart failure. Cardiology in the Young, 2005, 15, 333-344.	0.4	8
2	Nesiritide in the management of treatment refractory pediatric heart failure. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2006, 17, 101-107.	0.1	O
3	Advances in cardiac intensive care. Current Opinion in Pediatrics, 2006, 18, 503-511.	1.0	10
4	Future Pharmacologic Agents for Treatment of Heart Failure in Children. Pediatric Cardiology, 2006, 27, 533-551.	0.6	23
5	Administration of a Large Nesiritide Bolus Dose in a Pediatric Patient: Case Report and Review of Nesiritide Use in Pediatrics. Pharmacotherapy, 2006, 26, 277-280.	1.2	11
6	Nesiritide Therapy in a Term Neonate with Renal Disease. Pharmacotherapy, 2006, 26, 281-284.	1.2	4
7	B-type natriuretic peptide monitoring in the Pediatric ICU population. Paediatric Anaesthesia, 2007, 17, 793-799.	0.6	1
8	Unapproved Pediatric Drugs: Evidence for Use. Advances in Anesthesia, 2008, 26, 225-248.	0.5	1
9	Extracorporeal membrane oxygenation after cardiac arrest in children: what do we know?. European Journal of Cardio-thoracic Surgery, 2008, 33, 409-417.	0.6	63
10	Preliminary Experience With Nesiritide in Pediatric Patients Less Than 12 Months of Age. Journal of Intensive Care Medicine, 2008, 23, 321-328.	1.3	11
11	Nesiritide Improves Hemodynamics in Children with Dilated Cardiomyopathy: A Pilot Study. Pediatric Cardiology, 2009, 30, 26-34.	0.6	16
12	B-type Natriuretic Peptide: Diagnostic and Therapeutic Applications in Infants and Children. Journal of Intensive Care Medicine, 2011, 26, 183-195.	1.3	10
13	Pediatric Cardiovascular Drug Dosing in Critically Ill Children and Extracorporeal Membrane Oxygenation. Journal of Cardiovascular Pharmacology, 2011, 58, 126-132.	0.8	32
14	Acute Kidney Injury and Critical Cardiac Disease. World Journal for Pediatric & Disease. World Disease	0.3	11
15	Pharmacotherapy in Neonatal and Pediatric Extracorporeal Membrane Oxygenation (ECMO). Current Drug Metabolism, 2012, 13, 767-777.	0.7	33
16	The Impact of Extracorporeal Life Support and Hypothermia on Drug Disposition in Critically III Infants and Children. Pediatric Clinics of North America, 2012, 59, 1183-1204.	0.9	31
17	Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery. Current Vascular Pharmacology, 2015, 14, 63-72.	0.8	0
18	Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1133-1142.	1.5	18

#	Article	IF	CITATIONS
19	Postoperative Renal Management, Fluid/Electrolyte Management and Acid–Base Disorders. , 2017, , 889-950.		1
20	Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. Journal of Thoracic Disease, 2018, 10, S629-S641.	0.6	110
21	Drugs and ECMO. , 2014, , 2767-2780.		0